Rank #1022BEAM

Beam Therapeutics Inc.

$27.88

1.16% (Daily)

Market Cap

$2.83B

Revenue

$55.70M

Rank by MCap

#1022

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. John M. Evans M.B.A.

Headquarters

Cambridge, MA

Employees

510

About Beam Therapeutics Inc.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody...